Protagonist Therapeutics (PTGX) Non-Current Debt (2019 - 2020)
Protagonist Therapeutics (PTGX) posted Non-Current Debt of $9.8 million for Q1 2020, little changed sequentially from $9.8 million in Q4 2019.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) Non-Current Debt (2019 - 2020) Analysis & Trends
Protagonist Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $9.8 million in Q1 2020.
- Quarterly Non-Current Debt changed N/A year-over-year to $9.8 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $9.8 million (changed N/A YoY) and the FY2019 annual result came in at $9.8 million, changed N/A from the prior year.
- Non-Current Debt steadied at $9.8 million in Q1 2020 per PTGX's latest filing, from $9.8 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.8 million in Q1 2020 and troughed at $9.8 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - | - |